ProShares UltraShort NASDAQ Biotechnology
19 hedge funds and large institutions have $46.6M invested in ProShares UltraShort NASDAQ Biotechnology in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Holders
19
Holding in Top 10
1
Calls
$24M
Puts
$4.05M
Top Buyers
| 1 | +$12.2M | |
| 2 | +$4.83M | |
| 3 | +$3.01M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.5M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.16M |
Top Sellers
| 1 | -$2.87M | |
| 2 | -$579K | |
| 3 | -$469K | |
| 4 |
Morgan Stanley
New York
|
-$373K |
| 5 |
ID
Integral Derivatives
New York
|
-$319K |